
Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
MONTREAL, CANADA -- (Marketwired) -- 05/24/16 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) announces that it has been notified by its partner, TaiMed Biologics, Inc., of the preliminary results for the primary end point of the phase III trial …